Survival Plateau Observed After ICI Therapy in Advanced Melanoma
Source: Cancer Therapy Advisor, August 2024
Patients with advanced melanoma reach a plateau in survival after treatment with immune checkpoint inhibitors (ICIs), according to real-world data published in JAMA Network Open.
This study included 2490 patients with advanced melanoma who were enrolled in the Dutch Melanoma Treatment Registry and were treated with first-line ICIs from 2012 to 2019. Most patients had an ECOG performance status of 1 or lower (n=2202) and normal lactate dehydrogenase levels (n=1715). A minority of patients had liver metastases (n=626), brain metastases (n=565), BRAF variants (n=980), and NRAS variants (n=719).
The patients were treated with anti-PD-1 therapy (n=1409), ipilimumab monotherapy (n=601), and ipilimumab plus nivolumab (n=480). The median follow-up was 55.8 months.